GLP-1 Medications and Type 2 Diabetes: What You Need to Know
Before GLP-1 medications became famous for weight loss, they were diabetes drugs. Ozempic (semaglutide) and Mounjaro (tirzepatide) were both originally approved for the management of type 2 diabetes — and understanding that context helps explain why people with T2D experience the medications somewhat differently to those without it.
How GLP-1 Medications Work for Type 2 Diabetes
In people with type 2 diabetes, insulin secretion is impaired and the body's response to insulin is reduced. GLP-1 medications address several aspects of this simultaneously.
They stimulate insulin secretion — but only when blood glucose is elevated. This is called glucose-dependent insulin secretion, and it's one of the key advantages over some older diabetes medications. Because GLP-1 drugs only drive insulin release when blood sugar is actually high, the risk of dangerously low blood sugar (hypoglycaemia) is much lower than with medications that force insulin release regardless of glucose levels.
They suppress glucagon. Glucagon is a hormone that tells the liver to release stored glucose into the bloodstream. In people with T2D, glucagon is often overactive, contributing to elevated blood sugar even when fasting. GLP-1 medications suppress glucagon release, helping to lower fasting blood glucose levels.
They slow gastric emptying. This reduces the speed at which glucose from food enters the bloodstream, dampening post-meal blood sugar spikes — which are a significant problem for people with T2D.
The HbA1c Results
HbA1c is a measure of average blood sugar over approximately three months. In the clinical trials that supported Ozempic's approval for T2D, semaglutide at 1.0mg reduced HbA1c by approximately 1.5 percentage points — clinically meaningful for most people with T2D. At 2.0mg, the reduction was slightly greater. Tirzepatide (Mounjaro) in its T2D trials achieved HbA1c reductions of 2.0–2.3 percentage points at the highest doses, making it among the most effective oral or injectable diabetes medications currently available.
Why Weight Loss Is Lower in People with T2D
The STEP 2 trial — which studied semaglutide specifically in people with obesity and type 2 diabetes — found average weight loss of about 9.6% of body weight, compared to 14.9% in STEP 1 (similar participants without T2D). This pattern is consistent across the literature: people with type 2 diabetes tend to lose less weight on GLP-1 medications than those without it.
Several factors contribute to this. Some diabetes medications that people may be taking alongside GLP-1 drugs can promote weight gain or blunt weight loss (certain older diabetes medications, including some sulphonylureas and thiazolidinediones). Insulin resistance itself can make weight loss harder. And the metabolic environment in T2D differs in ways that may affect the medication's weight-loss action.
A 9.6% average weight loss is still clinically significant — particularly for people with T2D, where even a 5–10% reduction in body weight produces meaningful improvements in glycaemic control, blood pressure and cardiovascular risk. The lower average compared to non-diabetic populations doesn't make it less valuable in this context.
Cardiovascular Benefits
A major development in the understanding of GLP-1 medications is that they appear to provide cardiovascular benefits beyond their blood sugar and weight effects. The LEADER trial for liraglutide and SUSTAIN-6 for semaglutide both demonstrated reductions in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in people with T2D at high cardiovascular risk.
This has led to GLP-1 medications being recommended in some guidelines specifically for people with T2D who have established cardiovascular disease — not just to manage blood sugar, but to reduce the risk of heart attack and stroke. It's one of the reasons these medications occupy such a prominent position in modern diabetes management.
Managing Both Blood Sugar and Weight
For people with T2D who are using a GLP-1 medication primarily for diabetes management, monitoring both blood glucose and body weight over time provides a more complete picture of how the medication is working. Weight loss in T2D is often therapeutic in its own right — improving insulin sensitivity, reducing the dose of other medications needed, and in some cases contributing to diabetes remission in people who were recently diagnosed.
Tracking weight over time is relevant for this population just as it is for people using GLP-1 drugs primarily for weight management. Understanding how your weight is trending — and how that correlates with your glucose management — gives you better information to bring to your prescriber appointments.
Track your weight alongside your injections
Whether you're on Ozempic for diabetes management or Wegovy for weight loss, The GLP-1 HQ tracker logs each injection with date and dose and tracks your weight over time. Free, private, and no account needed.
Open the tracker →Hypoglycaemia Risk
GLP-1 medications on their own carry a very low risk of hypoglycaemia (blood sugar going too low) because of the glucose-dependent mechanism described above — they only promote insulin release when blood sugar is actually elevated. However, if you're using a GLP-1 medication alongside other diabetes medications that do carry hypoglycaemia risk — particularly insulin or sulphonylureas — the combination can increase that risk, particularly if your doses aren't adjusted to reflect your improved blood sugar control. This is an important conversation to have with your prescriber when starting a GLP-1 medication if you're already on insulin or other agents.
The Future: Remission and Beyond
One of the most significant developments in diabetes medicine in recent years is evidence that significant weight loss — particularly in people with recently diagnosed or well-controlled T2D — can lead to diabetes remission. The DiRECT trial showed this with intensive dietary intervention. GLP-1 medications, which produce sustained weight loss, are being studied for their potential to achieve similar outcomes in people with T2D who also have significant obesity. It's an evolving area, and one that makes the weight-tracking aspect of GLP-1 therapy particularly relevant for this population.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice for people with type 2 diabetes or any other condition. Managing diabetes involves multiple factors and any changes to medication or monitoring should be made in consultation with your treating healthcare team.